Literature DB >> 6128357

Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness.

S R Grewe, S C Chan, J M Hanifin.   

Abstract

Previous studies have documented that leukocytes from atopic individuals show reduced cyclic AMP (cAMP) responsiveness to isoproterenol, histamine, and prostaglandin E1. We questioned whether this blunted response was due to rapid enzymic breakdown of cAMP. We measured cAMP-phosphodiesterase activity in mononuclear leukocytes of patients with atopic dermatitis and allergic rhinitis and noted consistent, significantly elevated levels. Kinetic studies showed differences in two of three leukocyte enzyme forms between normals and patients. Isolated lymphocytes from atopic dermatitis patients lacked a low Km phosphodiesterase form and showed an increase in the high Km, high-activity form seen in normal monocytes. The increased phosphodiesterase activity provides an explanation for the blunted cAMP responsiveness in atopic leukocytes and may reflect a basic biochemical characteristic relevant to abnormal immunocellular regulation in atopic disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6128357     DOI: 10.1016/0091-6749(82)90008-2

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  27 in total

Review 1.  Prediction of the development of IgE-mediated atopic disorders and environmental engineering for their control.

Authors:  B A Chowdhury; R K Chandra
Journal:  Clin Rev Allergy       Date:  1989

2.  Ontogenetic changes in adenylate cyclase, cyclic AMP phosphodiesterase and calmodulin in chick ventricular myocardium.

Authors:  P M Epstein; D M Andrenyak; C J Smith; A J Pappano
Journal:  Biochem J       Date:  1987-04-15       Impact factor: 3.857

Review 3.  Beta adrenergic receptors in keratinocytes.

Authors:  Raja K Sivamani; Susanne T Lam; R Rivkah Isseroff
Journal:  Dermatol Clin       Date:  2007-10       Impact factor: 3.478

Review 4.  Dermatology.

Authors:  M H Rustin
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

Review 5.  Environmental risk factors and their role in the management of atopic dermatitis.

Authors:  Robert Kantor; Jonathan I Silverberg
Journal:  Expert Rev Clin Immunol       Date:  2016-07-28       Impact factor: 4.473

6.  Differential effect of phosphodiesterase inhibitors on IL-13 release from peripheral blood mononuclear cells.

Authors:  N Yoshida; Y Shimizu; K Kitaichi; K Hiramatsu; M Takeuchi; Y Ito; H Kume; K Yamaki; R Suzuki; E Shibata; T Hasegawa; K Takagi
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

7.  A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.

Authors:  Aman Samrao; Trista M Berry; Renato Goreshi; Eric L Simpson
Journal:  Arch Dermatol       Date:  2012-08

8.  Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.

Authors:  K H Banner; N M Roberts; C P Page
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 9.  Pharmacophysiology of atopic dermatitis.

Authors:  J M Hanifin
Journal:  Clin Rev Allergy       Date:  1986-02

Review 10.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.